CN112138066A - Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity - Google Patents
Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity Download PDFInfo
- Publication number
- CN112138066A CN112138066A CN202010938422.9A CN202010938422A CN112138066A CN 112138066 A CN112138066 A CN 112138066A CN 202010938422 A CN202010938422 A CN 202010938422A CN 112138066 A CN112138066 A CN 112138066A
- Authority
- CN
- China
- Prior art keywords
- solanum nigrum
- tumor
- extract
- black nightshade
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000002594 Solanum nigrum Nutrition 0.000 title claims abstract description 103
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 32
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 31
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 23
- 230000035945 sensitivity Effects 0.000 title claims abstract description 17
- 230000001965 increasing effect Effects 0.000 title claims abstract description 16
- 240000002307 Solanum ptychanthum Species 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 26
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 22
- 230000004048 modification Effects 0.000 claims abstract description 10
- 238000012986 modification Methods 0.000 claims abstract description 10
- 108010033040 Histones Proteins 0.000 claims abstract description 9
- 230000011987 methylation Effects 0.000 claims abstract description 8
- 238000007069 methylation reaction Methods 0.000 claims abstract description 8
- 244000061457 Solanum nigrum Species 0.000 claims description 95
- 230000000259 anti-tumor effect Effects 0.000 claims description 39
- 239000000126 substance Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 17
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 claims description 12
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical group O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 claims description 12
- 229940031352 solanine Drugs 0.000 claims description 12
- 238000000227 grinding Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002584 gefitinib Drugs 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 229940100691 oral capsule Drugs 0.000 claims description 3
- 229940096978 oral tablet Drugs 0.000 claims description 3
- 239000007935 oral tablet Substances 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 206010059866 Drug resistance Diseases 0.000 abstract description 9
- 230000002159 abnormal effect Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 101001027928 Cellulosimicrobium cellulans Type II methyltransferase M.AluI Proteins 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 235000008406 SarachaNachtschatten Nutrition 0.000 description 2
- 241000207763 Solanum Species 0.000 description 2
- 235000004790 Solanum aculeatissimum Nutrition 0.000 description 2
- 235000008424 Solanum demissum Nutrition 0.000 description 2
- 235000018253 Solanum ferox Nutrition 0.000 description 2
- 235000000208 Solanum incanum Nutrition 0.000 description 2
- 235000013131 Solanum macrocarpon Nutrition 0.000 description 2
- 235000009869 Solanum phureja Nutrition 0.000 description 2
- 235000000341 Solanum ptychanthum Nutrition 0.000 description 2
- 235000017622 Solanum xanthocarpum Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 101100369989 Mus musculus Tnfaip3 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of black nightshade or black nightshade extract in increasing the sensitivity of antibiotics or antitumor drugs, belonging to the technical field of medicines. The research of the invention finds that the black nightshade or black nightshade extract is used in combination with antibiotics or antitumor drugs, so that the sensitivity of the antibiotics or antitumor drugs can be increased, the dosage can be reduced, the safety of the drug use can be improved, and the treatment time can be prolonged. The pharmaceutical composition provided by the invention can intervene in DNA abnormal methylation and histone modification mechanism based on the black nightshade or black nightshade extract, and can be used for treating antibiotic or tumor drug resistance. The invention provides a new solution for the drug resistance of the existing antibiotics or antitumor drugs, fully utilizes and prolongs the life cycle of the existing drugs, and is more in line with the current pharmaceutical industry level and the current medical investment situation in principle from the medical economy.
Description
Technical Field
The invention relates to an application of black nightshade or black nightshade extract in increasing the sensitivity of antibiotics or antitumor drugs, belonging to the technical field of medicines.
Background
Antibiotics and antitumor drugs are the main means for treating infectious diseases and tumors, respectively, however, the problem of drug resistance of bacteria and tumors is getting more serious due to the evolution mechanism of bacteria and tumors themselves and the long-term large dose use of antibiotics and antitumor drugs.
The natural medicine contains rich bioactive substances, and a large number of researches show that the traditional Chinese medicine and the western medicine can be combined in a synergistic manner through scientific compatibility, so that the sensitivity is increased, the dosage is reduced, and the toxic and side effects are reduced. The traditional Chinese medicine is used together with antibiotics and antitumor drugs, and the special advantages in the aspect of improving the drug resistance of bacteria and tumors are possibly played.
The black nightshade has the effects of clearing away heat and toxic materials, promoting blood circulation, removing blood stasis, inducing diuresis, relieving swelling, relieving cough and eliminating phlegm. Is clinically used for treating various inflammations and tumors, and the anti-tumor effect of the traditional Chinese medicine is a research hotspot of scholars at home and abroad. The combination of solanine and Doxorubicin (DOX) is also found to obviously improve the killing effect of DOX on leukemia K562/ADR cells, reverse the multidrug resistance of cells, and the mechanism of the combination is related to the inhibition of JNK activity, the down-regulation of MRP1 protein expression and the increase of accumulation of DOX in cells.
Epigenetic and protein modifications play an important role in bacterial and tumor resistance, while traditional Chinese medicines can interfere with DNA abnormal methylation and histone modification. Epigenetics mainly includes DNA methylation, histone modification, chromatin remodeling, post-transcriptional regulation, etc., and post-translational protein modification refers to chemical modification by adding different chemical groups to amino acid residues of proteins, both of which largely expand the coding capacity of bacterial and tumor cell genomes and promote the formation of drug resistance. Hsieh HY and the like carry out systematic epigenetic study on 48491 compounds in 3294 traditional Chinese medicines, and the result shows that 29.8 percent of traditional Chinese medicines or compound medicines can regulate and control functions of epigenome and miRNA. The solanum nigrum and the extract thereof have the effects of intervening the abnormal methylation of DNA and histone modification of bacteria and tumor cells, but no research on the combination treatment of bacteria and tumor resistance by the solanum nigrum, antibiotics and antitumor drugs based on the regulation and control mechanism of epigenetic inheritance exists at present.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides the application of the black nightshade or the black nightshade extract in increasing the sensitivity of antibiotics or antitumor drugs.
In order to achieve the purpose, the invention adopts the technical scheme that: the application of Solanum nigrum or Solanum nigrum extract in increasing antibiotic or antitumor drug sensitivity is provided.
The research of the invention finds that the black nightshade or the black nightshade extract can interfere DNA abnormal methylation and histone modification, can be combined with antibiotics or antitumor drugs, and can be used for treating bacterial or tumor drug resistance, increasing drug sensitivity, reducing dosage and prolonging treatment time. Experiments prove that the invention uses the black nightshade or black nightshade extract together with antibiotics or antitumor drugs, the black nightshade can intervene abnormal methylation of DNA and histone modification of bacteria and tumor cells, enhance the sensitivity of the drugs, improve indexes such as minimum inhibitory concentration, tumor inhibition rate and the like, improve the curative effect and provide a new scheme for solving the problem of drug resistance of bacteria and tumors in clinic.
As a preferred embodiment of the application of the invention, the black nightshade or black nightshade extract intervenes DNA abnormal methylation and histone modification, increasing the sensitivity of antibiotics or antitumor drugs.
In a second aspect, the present invention provides a pharmaceutical composition for increasing sensitivity to an antibiotic or an anti-tumor drug, the pharmaceutical composition comprising an antibiotic or an anti-tumor drug, and Solanum nigrum or an extract of Solanum nigrum.
As a preferred embodiment of the pharmaceutical composition of the present invention, the black nightshade is a fresh black nightshade fruit, and the black nightshade extract is solanine.
As a preferable embodiment of the pharmaceutical composition of the present invention, the anti-tumor drug is an anti-tumor biological drug or an anti-tumor chemical drug.
In a preferred embodiment of the pharmaceutical composition of the present invention, the anti-tumor biological agent is nivolumab and the anti-tumor chemical agent is gefitinib.
In a preferred embodiment of the pharmaceutical composition of the present invention, the mass ratio of the black nightshade or black nightshade extract to the antibiotic is (50: 1) - (1: 1), the mass ratio of the black nightshade or black nightshade extract to the anti-tumor biological drug is (50: 1) - (1: 1), and the mass ratio of the black nightshade or black nightshade extract to the anti-tumor chemical drug is (100: 1) - (1: 1).
In a preferred embodiment of the pharmaceutical composition of the present invention, the mass ratio of the black nightshade or black nightshade extract to the antibiotic is (30: 1) - (5: 1), the mass ratio of the black nightshade or black nightshade extract to the anti-tumor biological drug is (20: 1) - (5: 1), and the mass ratio of the black nightshade or black nightshade extract to the anti-tumor chemical drug is (30: 1) - (10: 1).
In a third aspect, the present invention provides a preparation method of the above pharmaceutical composition, comprising the following steps:
(1) crushing Solanum nigrum fruit into coarse powder, adding 6 times of water, stirring and extracting at 20 ℃ for 0.5-4 hours for 2 times, monitoring the content of solanine in an extracting solution by adopting a high performance liquid chromatography in the extraction process, ensuring that the content of the solanine in the obtained freeze-dried powder is 3-6mg/g, stopping extraction when the corresponding content is reached, combining the extracting solutions, filtering, centrifuging, filling a centrifugate into a freeze-drying box, freeze-drying, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
or grinding the Solanum nigrum extract and sieving with a 200-mesh sieve to obtain fine powder for later use;
(2) placing antibiotic or antitumor drug into a stirrer, stirring uniformly, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
(3) and (3) mixing the fine powder obtained in the steps (1) to (2), uniformly stirring, putting into an oven, drying at 40 ℃, cooling, extracting, grinding, and sieving with a 200-mesh sieve to obtain the pharmaceutical composition.
In a fourth aspect, the invention provides an oral tablet or capsule, which comprises the pharmaceutical composition and pharmaceutically acceptable auxiliary materials. The preparation method of the oral tablet or capsule comprises the following steps: mixing the medicinal composition and pharmaceutically acceptable adjuvants uniformly.
Compared with the prior art, the invention has the beneficial effects that: the research of the invention finds that the black nightshade or black nightshade extract is used in combination with antibiotics or antitumor drugs, so that the sensitivity of the antibiotics or antitumor drugs can be increased, the dosage is reduced, and the treatment time is prolonged. The pharmaceutical composition provided by the invention can intervene in DNA abnormal methylation and histone modification mechanism based on the black nightshade or black nightshade extract, and can be used for treating antibiotic or tumor drug resistance. The invention provides a new solution for the drug resistance of the existing antibiotics or antitumor drugs, fully utilizes and prolongs the life cycle of the existing drugs, and is more in line with the current pharmaceutical industry level and the current medical investment situation in principle from the medical economy.
Drawings
FIG. 1 is a photograph showing the tumor-bearing mice of the effect example 6 after they died, wherein (a) from left to right are photographs showing the tumor-bearing mice of examples 22 to 26 after they died, respectively, and (b) from left to right are photographs showing the tumor-bearing mice of comparative examples 7 to 8 after they died, respectively.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
A pharmaceutical composition for increasing antibiotic drug sensitivity comprises an antibiotic and black nightshade, wherein the mass ratio of the antibiotic to the black nightshade and the type of the antibiotic in the pharmaceutical composition are shown in Table 1.
The preparation method of the pharmaceutical composition of this example comprises:
(1) crushing Solanum nigrum fruit into coarse powder, adding 6 times of water, stirring and extracting at 20 ℃ for 0.5-4 hours for 2 times, monitoring the content of solanine in an extracting solution by adopting a high performance liquid chromatography in the extraction process, ensuring that the content of the solanine in the obtained freeze-dried powder is 3-6mg/g, stopping extraction when the corresponding content is reached, combining the extracting solutions, filtering, centrifuging, filling a centrifugate into a freeze-drying box, freeze-drying, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
(2) putting the antibiotics into a stirrer, stirring uniformly, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
(3) and (3) mixing the fine powder obtained in the steps (1) to (2), uniformly stirring, putting into an oven, drying at 40 ℃, cooling, extracting, grinding, and sieving with a 200-mesh sieve to obtain the pharmaceutical composition.
Examples 2 to 7 and comparative examples 1 to 2
The pharmaceutical compositions of examples 2-7 comprise antibiotics and black nightshade, and the mass ratio and the type of the antibiotics in the pharmaceutical compositions are shown in table 1. Comparative example 1 contained no solanum nigrum and comparative example 2 contained no antibiotics.
The preparation methods of the pharmaceutical compositions of examples 2-7 and comparative examples 1-2 are the same as example 1.
TABLE 1
Examples 8 to 14 and comparative examples 3 to 4
The pharmaceutical composition of examples 8 to 14 includes the antitumor drug and nightshade, and the mass ratio and the type of the antitumor drug of the pharmaceutical composition are shown in table 2. Comparative example 3 did not contain solanum nigrum and comparative example 4 did not contain anti-tumor biopharmaceuticals.
The preparation methods of the pharmaceutical compositions of examples 8 to 14 and comparative examples 3 to 4 are the same as example 1.
TABLE 2
Anti-tumor biological medicine | The mass ratio of the black nightshade to the anti-tumor biological medicine | |
Example 8 | Nivolumab | 50:1 |
Example 9 | Nivolumab | 20:1 |
Example 10 | Nivolumab | 10:1 |
Example 11 | Nivolumab | 5:1 |
Example 12 | Nivolumab | 1:1 |
Example 13 | Bevacizumab | 10:1 |
Example 14 | Adalimumab | 10:1 |
Comparative example 3 | Nivolumab | Contains no black nightshade |
Comparative example 4 | -- | Contains no antitumor biological medicine |
Examples 15 to 21 and comparative examples 5 to 6
The pharmaceutical composition of examples 15 to 21 includes an antitumor chemical and solanum nigrum, and the mass ratio and the type of the antitumor chemical of the pharmaceutical composition are shown in table 3. Comparative example 5 did not contain solanum nigrum and comparative example 6 did not contain anti-tumor chemicals.
The preparation methods of the pharmaceutical compositions of examples 15 to 21 and comparative examples 5 to 6 are the same as example 1.
TABLE 3
Anti-tumor chemical | The mass ratio of the black nightshade to the anti-tumor chemical medicine | |
Example 15 | Gefitinib | 100:1 |
Example 16 | Gefitinib | 30:1 |
Example 17 | Gefitinib | 20:1 |
Example 18 | Gefitinib | 10:1 |
Example 19 | Gefitinib | 1:1 |
Example 20 | 5-Fluorouracil | 20:1 |
Example 21 | Paclitaxel | 20:1 |
Comparative example 5 | Gefitinib | Contains no black nightshade |
Comparative example 6 | -- | Contains no antitumor chemical |
Examples 22 to 26 and comparative examples 7 to 8
The pharmaceutical compositions of examples 22 to 26 include the antitumor chemical and solanum nigrum, and the mass ratio and the type of the antitumor chemical of the pharmaceutical compositions are shown in table 4. Comparative example 7 contained no nightshade and comparative example 8 contained no anti-tumor chemicals.
The preparation methods of the pharmaceutical compositions of examples 22-26 and comparative examples 7-8 are the same as example 1.
TABLE 4
Effect example 1 in vitro antibacterial test
Drug-resistant strains such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii and the like are collected, a 96-well plate trace broth two-fold dilution method is adopted, the concentration multiple dilution of the antibacterial drug is 0.063-128mg/ml, the total concentration is 12, and the use amount of the black nightshade is respectively tested by a fixed dose method and a method of equivalent multiple dilution with the antibacterial drug. Several colonies, freshly grown overnight, were picked, adjusted to 0.5 McLeod concentration in MH broth by turbidimetry, and after 20h of incubation at 35 ℃ the Minimum Inhibitory Concentration (MIC) was read and the corresponding quality control standard strain was used as a control for each experiment.
The results of the above tests on the pharmaceutical compositions of examples 1 to 7 and comparative examples 1 to 2 are shown in Table 5.
TABLE 5
According to test results, the pharmaceutical composition disclosed by the invention in the embodiments 1-7 has a lower minimum inhibitory concentration; comparative example 1 contains no black nightshade, and has a higher minimum inhibitory concentration; comparative example 2 contains no antibiotic and has a higher minimum inhibitory concentration than the present invention.
In addition, in the pharmaceutical compositions of examples 2 to 4, when the mass ratio of the solanum nigrum to the antibiotic is (30: 1) to (5: 1), the minimum inhibitory concentration is lower.
Effect example 2 in vivo antibacterial experiment
Collection of penicillin-insensitive pneumonia chainsStreptococcus pneumoniae in blood culture medium (MH culture medium supplemented with 5% defibrinated sheep blood) at 35 deg.C and 5% CO2Environment (CO)2Incubator) for 16 h.
Establishing a mouse immune suppression model: reference method, mice were given intraperitoneal injections of 150, 100mg/kg Cyclophosphamide (CPM) on test day 1, day 4, respectively, to establish an immunosuppressive model.
Establishing a mouse streptococcus pneumoniae pneumonia model: single colony Streptococcus pneumoniae was inoculated into 10mL brain-heart attack solution with 5% CO2Culturing at 35 deg.C for 8-12 h. Diluting with sterile brain and heart invasion solution, collecting 500 μ L, adding 500 μ L0.2% agar, shaking, mixing to obtain Streptococcus pneumoniae bacterial suspension with final concentration of about 1 × 107CFU/mL, and standing at 42-45 deg.C.
The last day after the mice were injected with cyclophosphamide intraperitoneally, i.e., day 5 of the experiment, streptococcus pneumoniae bacterial suspension was instilled through the nasal cavity on a sterile operating table to carry out streptococcus pneumoniae infection. Before bacterial inoculation, 0.12mL of 1.0% sodium pentobarbital is intraperitoneally injected for anesthesia, when the whole muscle of the mouse is relaxed, the mouse is converted into an anesthesia state from excitation, four limbs are fixed on a fixer, the fixer is erected to enable the mouse to be upright, and incisors are fixed by thin lines. Sucking 50 μ L of the suspension of Streptococcus pneumoniae bacteria with a micro liquid feeder, slowly dripping from nasal cavity, and standing for 5min after dripping to allow the bacteria liquid to be fully sucked. After 5min of infection, the mice were released and returned to their cages for waking.
Examples 1-7 in vivo antibacterial action against mouse pneumonia
The infected mice were divided into 9 groups of 5 mice each, and the drugs of examples 1 to 7 and comparative examples 1 to 2 were administered, respectively. A blank control group of 7 was set and given physiological saline.
After 2h of infection, 2 mice in the blank control group were sacrificed, bilateral lung tissues were immediately isolated under aseptic conditions, weighed and placed in 1.0mL of sterile physiological saline, homogenized in a tissue disperser, and counted for colonies. While other mice were given drug/saline treatment. Each group was administered at a dose of 234mg/kg (equivalent to 1 g/day in humans) in 2 divided doses of 0.2ml each at 12 hour intervals.
24 hours after the first administration (i.e. 26 hours after infection), all mice were sacrificed, lung tissue was dissected and taken, weighed, homogenized, and bacteria were cultured and counted to calculate the bacteria content per gram of lung tissue. Statistical differences between drugs were compared using SPSS software for two independent sample t-tests. The results are shown in Table 6.
TABLE 6
According to test results, the pharmaceutical composition disclosed by the invention in the embodiments 1-7 has a strong in-vivo antibacterial effect; comparative example 1 contains no Solanum nigrum and has a low in vivo antibacterial effect; comparative example 2 contains no antibiotic and its in vivo antibacterial effect is inferior to the present invention.
In addition, in the pharmaceutical compositions of examples 2 to 4, when the mass ratio of the solanum nigrum to the antibiotic is (30: 1) to (5: 1), the in vivo antibacterial effect is stronger.
Effect example 3 inhibition Effect test on proliferation of human Lung cancer cell line A549
Adopting MTT method to prepare the human lung cancer A549 cells in logarithmic growth phase into the culture medium with the density of 5 multiplied by 104After the cell suspension was suspended in a volume of 10. mu.L/well in a 96-well plate, the culture medium was discarded after 24 hours of incubation. Each well was filled with 90. mu.L of serum-free medium, 10. mu.L of each of the solutions of group B of the above preparation examples was added to the administered group, and an equal volume of PBS solution was administered to the blank group. After continuing culturing for 36h, adding 10 mu L of 5mg/mL MTT solution into each well, incubating for 4h, stopping incubation, discarding the supernatant, adding 100 mu L of DMSO into each well, oscillating for 10min in a micro oscillator in a dark place, measuring the absorbance (A) value of each well by using an enzyme labeling instrument, measuring the absorbance (A) value for 6 times in parallel at a detection wavelength of 550nm and a reference wavelength of 690nm, and taking an average value. The inhibition rate of each of the solutions to be administered on the growth of A549 cells was calculated according to the following formula, and the half inhibitory concentration (IC50) was determined using SPSS software.
The cell growth inhibition rate was (1-mean a value of experimental group/mean a value of blank control group) × 100%.
The pharmaceutical compositions of examples 8 to 14, comparative examples 3 to 4, examples 15 to 21, and comparative examples 5 to 6 were subjected to the above-described tests. The results are shown in Table 7.
TABLE 7
Group of | IC50(nmol/L) |
Example 8 | 5989.2 |
Example 9 | 3908.1 |
Example 10 | 3344.1 |
Example 11 | 4756.5 |
Example 12 | 6942.2 |
Example 13 | 8327.9 |
Example 14 | 8857.5 |
Comparative example 3 | 6405.0 |
Comparative example 4 | 13118.9 |
Examples15 | 20.0 |
Example 16 | 5.3 |
Example 17 | 5.5 |
Example 18 | 16.0 |
Example 19 | 100.7 |
Example 20 | 288.4 |
Example 21 | 1005.8 |
Comparative example 5 | 20.1 |
Comparative example 6 | 13050.6 |
The test results show that the IC50 values of the pharmaceutical compositions of the invention in examples 8-14 and 15-21 are low; comparative example 3 and comparative example 5, which did not contain solanum nigrum, had higher IC50 values; comparative examples 4 and 6, which do not contain an anti-tumor chemical, have IC50 values higher than the present invention.
In addition, in the pharmaceutical compositions of examples 9 to 11, the mass ratio of the black nightshade to the antitumor biological agent is (20: 1) - (5: 1), and the IC50 value is lower; in the pharmaceutical compositions of examples 16 to 18, the weight ratio of the Solanum nigrum to the antitumor chemical is (30: 1) to (10: 1), and the IC50 value is lower.
Effect example 4 test for inhibition of proliferation of human Hodgkin lymphoma cell line L428
Using the MTT method, L428 cell line was cultured in DMEM medium containing 10% inactivated newborn calf serum, 100U/mL penicillin and 100. mu.g/mL streptomycin at 37 ℃ under 5% CO2Culturing under the condition, and taking cells in logarithmic growth phase for experiment. L428 and 90. mu.L of BJAB cell line were cultured in 96-well plates at a concentration of 2X 106/ml, 10. mu.L of LPBS was added to the blank control group, and 10. mu.L of the liquid medicine of the above preparation examples was added to the administration group, respectively, to give the final concentration of the drug (calculated as crude drug). A negative control group is prepared by adding different dosages of liquid medicine into the culture solution without cells. Setting 6 parallel wells, culturing cells for 24h after administration, adding 20 μ L of 5.0mg/mL MTT solution into each well, shaking and mixing uniformly, placing in an incubator for continuous incubation for 4h, discarding supernatant in each well, adding 100 μ L of LDMSO to stop reaction, shaking and mixing uniformly for 10min, after purple crystals in each well are completely dissolved, measuring the absorbance (A) at 490nm by using a calibrator, and calculating the half inhibitory concentration (IC50) by using SPSS software.
The pharmaceutical compositions of examples 8 to 14, comparative examples 3 to 4, examples 15 to 21, and comparative examples 5 to 6 were subjected to the above-described tests. The results are shown in Table 8.
TABLE 8
The test results show that the IC50 values of the pharmaceutical compositions of the invention in examples 8-14 and 15-21 are low; comparative example 3 and comparative example 5, which did not contain solanum nigrum, had higher IC50 values; comparative examples 4 and 6, which do not contain an anti-tumor chemical, have IC50 values higher than the present invention.
In addition, in the pharmaceutical compositions of examples 9 to 11, the mass ratio of the black nightshade to the antitumor biological agent is (20: 1) - (5: 1), and the IC50 value is lower; in the pharmaceutical compositions of examples 16 to 18, the weight ratio of the Solanum nigrum to the antitumor chemical is (30: 1) to (10: 1), and the IC50 value is lower.
Effect example 5 tumor suppression Rate test (lymphoma) for tumor-bearing mice
Tumor mouse model establishment: resuscitating mouse A20 lymphoma cells, adjusting concentration to 1 × 108The cell suspension of each/mL is inoculated in the axilla of the right forelimb of a BALB/c mouse, and subcutaneous tumor nodules with the diameter of about 0.5cm can be observed for 1 week, which indicates that the establishment of a tumor mouse model is successful.
Grouping and administration treatment: mice were divided into 18 groups of 10 mice depending on the treatment regimen and the experiment was started one week after tumor inoculation.
Tumor volumes were measured with a vernier caliper at 1, 3, 5, 7, 9, 11 d. 24h after the last administration, the orbital bleeding is measured for blood routine. After sacrifice, weights of spleen, thymus and tumor were measured, and organ index and tumor suppression rate were calculated.
The pharmaceutical compositions of examples 8 to 14, comparative examples 3 to 4, examples 15 to 21, and comparative examples 5 to 6 were subjected to the above-described tests. The results are shown in Table 9.
TABLE 9
The test results show that the tumor inhibition rates of the pharmaceutical compositions of the invention in examples 8-14 and 15-21 are high; comparative examples 3 and 5, which do not contain solanum nigrum, have a lower tumor inhibition than the present invention; comparative examples 4 and 6, which do not contain an antitumor chemical, have a lower tumor inhibition rate than the present invention.
In addition, in the pharmaceutical compositions of examples 9 to 11, the weight ratio of the solanum nigrum to the anti-tumor biological agent is (20: 1) - (5: 1), and the tumor inhibition rate is higher; in the pharmaceutical compositions of examples 16 to 18, the ratio by mass of solanum nigrum to the anti-tumor chemical is (30: 1) to (10: 1), and the anti-tumor rate is higher.
Effect example 6 drug effect experiment in tumor-bearing mice (Lung cancer)
The mice were revived and 10 mice were randomly selected as blank control. The right axilla of the remaining mice were inoculated subcutaneously with Lewis cells (1X 10)7mL), 0.2mL each, after 24h, were randomly divided into 7 groups of 10. The tested groups are respectively and regularly administrated with the medicaments of examples 22 to 28 and comparative examples 7 to 8 by intragastric administration for 1 time per day and are continuously administrated for 42 days.
24h after the last administration, the orbital bleeding is measured for blood routine. After sacrifice, the liver, kidney, and tumor weights were weighed, and the organ index was calculated, and the results are shown in table 10 and fig. 1.
Watch 10
According to the test results, the survival rate of the pharmaceutical composition of the embodiment 22-26 is higher; comparative example 7 does not contain solanum nigrum, and the survival rate is lower than that of the present invention; comparative example 8, which does not contain an anti-tumor chemical, has a lower survival rate than the present invention. Based on the tumor weight data analysis, the example tumor/body weight ratios were less than the comparative examples, indicating that the combination of chemicals with solanum nigrum inhibits tumor growth. According to the analysis of the organ coefficient data, the difference between each group in the examples and the comparative example is not significant, and the black nightshade has no obvious liver and kidney toxicity.
In the pharmaceutical compositions of examples 23 to 25, the ratio by mass of solanum nigrum to the antitumor agent is (20: 1) to (5: 1), and the survival rate is higher.
Effect example 7 analysis of DNA methylase Activity
The effect of various doses of solanine on the activity of M.AluI methylase was examined, and no drug treatment was used as a control. 10 μ L of methylase protection reaction system (1 μ L of lambda DNA; 1 μ L of drug; 1 μ L of LSAM; 1 μ L of Alu I; 1 μ L of buffer solution; 5 μ L of LH2O), placing in a 37 ℃ water bath, after 2h, carrying out Alu I enzyme digestion reaction, 20 μ L of reaction system (5 μ L of the methylase cleavage protection reaction system; 2 μ L of buffer solution, 1 μ L of LAlu I, 12 μ L of LH2O), 37 ℃ for 2h, and 0.7% gel electrophoresis.
The test result shows that the lambda DNA is cut into a plurality of strips by the M.AluI enzyme compared with the control group in the solanine treatment group, which shows that the solanine influences the activity of the M.AluI enzyme, so that the lambda DNA can not be modified by the M.AluI enzyme, and thus the lambda DNA is cut by the enzyme.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The application of Solanum nigrum or Solanum nigrum extract in increasing antibiotic or antitumor drug sensitivity is provided.
2. The use of claim 1, wherein the Solanum nigrum or Solanum nigrum extract intervenes in DNA aberrant methylation and histone modification, increasing the sensitivity to antibiotics or anti-tumor drugs.
3. A pharmaceutical composition for increasing sensitivity to antibiotics or anti-tumor drugs, comprising an antibiotic or anti-tumor drug, and solanum nigrum or an extract of solanum nigrum.
4. The pharmaceutical composition of claim 3, wherein the Solanum nigrum is fresh Solanum nigrum fruit and the Solanum nigrum extract is solanine.
5. The pharmaceutical composition of claim 3, wherein the anti-neoplastic drug is an anti-neoplastic biologic or an anti-neoplastic chemical.
6. The pharmaceutical composition of claim 5, wherein the anti-tumor biologic is nivolumab and the anti-tumor chemical is gefitinib.
7. The pharmaceutical composition according to claim 3, wherein the mass ratio of the Solanum nigrum or the Solanum nigrum extract to the antibiotic is (50: 1) to (1: 1), the mass ratio of the Solanum nigrum or the Solanum nigrum extract to the anti-tumor biological drug is (50: 1) to (1: 1), and the mass ratio of the Solanum nigrum or the Solanum nigrum extract to the anti-tumor chemical drug is (100: 1) to (1: 1).
8. The pharmaceutical composition according to claim 7, wherein the weight ratio of the Solanum nigrum or the Solanum nigrum extract to the antibiotic is (30: 1) - (5: 1), the weight ratio of the Solanum nigrum or the Solanum nigrum extract to the anti-tumor biological drug is (20: 1) - (5: 1), and the weight ratio of the Solanum nigrum or the Solanum nigrum extract to the anti-tumor chemical drug is (30: 1) - (10: 1).
9. A process for the preparation of a pharmaceutical composition according to any one of claims 3 to 8, comprising the steps of:
(1) crushing Solanum nigrum fruit into coarse powder, adding 6 times of water, stirring and extracting at 20 ℃ for 0.5-4 hours for 2 times, monitoring the content of solanine in an extracting solution by adopting a high performance liquid chromatography in the extraction process, ensuring that the content of the solanine in the obtained freeze-dried powder is 3-6mg/g, stopping extraction when the corresponding content is reached, combining the extracting solutions, filtering, centrifuging, filling a centrifugate into a freeze-drying box, freeze-drying, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
or grinding the Solanum nigrum extract and sieving with a 200-mesh sieve to obtain fine powder for later use;
(2) placing antibiotic or antitumor drug into a stirrer, stirring uniformly, extracting and grinding to obtain fine powder which is sieved by a 200-mesh sieve for later use;
(3) and (3) mixing the fine powder obtained in the steps (1) to (2), uniformly stirring, putting into an oven, drying at 40 ℃, cooling, extracting, grinding, and sieving with a 200-mesh sieve to obtain the pharmaceutical composition.
10. An oral tablet or capsule, wherein the tablet or capsule comprises the pharmaceutical composition of any one of claims 3 to 8 and pharmaceutically acceptable excipients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010938422.9A CN112138066B (en) | 2020-09-09 | 2020-09-09 | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010938422.9A CN112138066B (en) | 2020-09-09 | 2020-09-09 | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112138066A true CN112138066A (en) | 2020-12-29 |
CN112138066B CN112138066B (en) | 2022-02-25 |
Family
ID=73890109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010938422.9A Active CN112138066B (en) | 2020-09-09 | 2020-09-09 | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112138066B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114393A1 (en) * | 1999-12-30 | 2003-06-19 | Mordechai Liscovitch | Use of steroidal alkaloids to reverse multidrug resistance |
US20040247715A1 (en) * | 2003-06-05 | 2004-12-09 | G & E Herbal Biotechnology Co., Ltd. | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
CN102397398A (en) * | 2011-11-23 | 2012-04-04 | 暨南大学 | Chinese medicinal composition for reversing multi-drug resistance of tumor and preparation method and application thereof |
CN104306807A (en) * | 2014-11-18 | 2015-01-28 | 广东省中医院 | Compound preparation for treating advanced lung cancer and preparing method thereof |
CN106728912A (en) * | 2017-01-06 | 2017-05-31 | 林丽珠 | Treat the composition of lung cancer and the application for preparing treatment lung-cancer medicament |
CN107536912A (en) * | 2017-09-29 | 2018-01-05 | 南京仙草堂生物科技有限公司 | A kind of medicine for adjuvant treatment of breast cancer and preparation method thereof |
-
2020
- 2020-09-09 CN CN202010938422.9A patent/CN112138066B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114393A1 (en) * | 1999-12-30 | 2003-06-19 | Mordechai Liscovitch | Use of steroidal alkaloids to reverse multidrug resistance |
US20040247715A1 (en) * | 2003-06-05 | 2004-12-09 | G & E Herbal Biotechnology Co., Ltd. | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract |
CN102397398A (en) * | 2011-11-23 | 2012-04-04 | 暨南大学 | Chinese medicinal composition for reversing multi-drug resistance of tumor and preparation method and application thereof |
CN104306807A (en) * | 2014-11-18 | 2015-01-28 | 广东省中医院 | Compound preparation for treating advanced lung cancer and preparing method thereof |
CN106728912A (en) * | 2017-01-06 | 2017-05-31 | 林丽珠 | Treat the composition of lung cancer and the application for preparing treatment lung-cancer medicament |
CN107536912A (en) * | 2017-09-29 | 2018-01-05 | 南京仙草堂生物科技有限公司 | A kind of medicine for adjuvant treatment of breast cancer and preparation method thereof |
Non-Patent Citations (5)
Title |
---|
YING-JIE YI,等: "Solanine reverses multidrug resistance in human myelogenous leukemia K562/ADM cells by downregulating MRP1 expression", 《ONCOLOGY LETTERS》 * |
张翠娟等: "DNA甲基化和组蛋白修饰在肿瘤中的作用", 《中国现代普通外科进展》 * |
朱聪等: "龙葵碱对白血病K562/ADR细胞多药耐药性的逆转作用及其分子机制", 《肿瘤》 * |
武凤霞等: "龙葵抗肿瘤机制及其研究进展", 《中药材》 * |
闫霞等: "龙葵碱抗肿瘤作用及机制", 《世界中医药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112138066B (en) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110545820B (en) | Application of kelimycin and pharmaceutically acceptable salt thereof in preparing medicaments for treating and/or preventing tumors | |
TW201618801A (en) | Pharmaceutical composition used for assisting chemotherapy drug and application thereof | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
WO2007124625A1 (en) | Limax polysaccharides, the production process and the use of the same | |
CN112138066B (en) | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity | |
CN116948901A (en) | Application of Weissella antrum D-2 extracellular polysaccharide in inhibiting colon cancer cells | |
CN108586626B (en) | Preparation method and application of tetrastigma hemsleyanum Diels et Gilg oligosaccharide | |
US9629385B2 (en) | Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer | |
CN100574757C (en) | The compositions of acetylcysteine or its salt and anti-infectives | |
US11167002B2 (en) | Pharmaceutical composition for the treatment of malignant neoplasms including sarcoma, cancers of liver, lung, bladder, blood and cervical, treatment of infectious diseases and type 2 diabetes | |
CN110251538B (en) | Application of Yao medicine and Chinese artichoke extract in preparation of medicine for treating pneumonia caused by Klebsiella infection | |
CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
CN106924235A (en) | Application of the usnic acid in antineoplastic sensitizer is prepared | |
CN108815239B (en) | Application of pharmaceutical composition in preparation of antibacterial drugs | |
CN108836975B (en) | New application of multinoside | |
CN106924225A (en) | Application of the magnolol in antineoplastic sensitizer is prepared | |
CN100438881C (en) | Application of crocodile blood in process for preparing anticancer antivirus and immunity improving medicine and health caring food | |
CN106924253A (en) | Application of 8- the third dicyan jamaicins in antineoplastic sensitizer is prepared | |
CN106727733B (en) | Combined medicine for fresh cordyceps sinensis antitumor chemotherapy and application thereof | |
CN1064241C (en) | Snake poison anti-cancer medicine and its prepn. | |
CN115521385B (en) | Armillarisin mycelium polysaccharide, preparation method thereof and application thereof in resisting tumors | |
CN113499328B (en) | Application of licochalcone A in preparation of drugs for resisting clostridium difficile infection | |
CN110841054B (en) | Combination of antibacterial peptide PFR and cytarabine and anticancer effect thereof | |
CN109953999B (en) | Composition comprising Ganoderma polysaccharide and Polyporus polysaccharide with immunity enhancing effect | |
CN117942349A (en) | Andrographolide-isatis root polysaccharide composition and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |